ATP binding cassette subfamily C member 4 (PEL blood group)Genealiases: MOAT-B · MOATB · MRP4
Q-omics provides the consensus-scored ABCC4 profile across patient tissues and cancer cell-line models. ABCC4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ABCC4 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, ABCC4 RNA expression shows 19,694 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, HNSC, and UVM as cancer lineages where ABCC4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ABCC4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ABCC4 survival associations across molecular data types. ABCC4 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ABCC4 RNA expression–survival associations across cancer types. High ABCC4 expression shows unfavorable associations in UVM, MESO, UCEC and ACC, but favorable associations in KIRC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ABCC4 RNA expression.
This table summarizes ABCC4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ABCC4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ABCC4 shows lower tumor expression in THCA, LUSC, LUAD and UCEC and higher tumor expression in HNSC and BRCA. The HNSC box plot shows higher ABCC4 RNA expression in tumor versus normal tissue (log2 FC = +1.255, t-test p < 0.001).
This table shows molecular features associated with ABCC4 in patient tissues and cancer cell lines. In patient samples, ABCC4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ABCC4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
